EXOZ

eXoZymes Inc. Common Stock

EXOZ

Market cap $112M

Overview Fund Activity

13.39 USD

-0.23

1.69%

At close Updated Sep 18, 11:00 AM EDT

1 day

-1.69%

5 days

4.77%

1 month

37.19%

3 months

8.42%

6 months

-11.62%

Year to date

-9.59%

1 year

54.8%

5 years

54.8%

10 years

54.8%

About: EXoZymes Inc is focused on using a biomanufacturing platform to create valuable biochemicals, including Active Pharmaceutical Ingredients or APIs, biofuels, food flavors, and cosmetics, offering a sustainable alternative to traditional chemical production methods.

Employees: 31

Healthcare Biotechnology

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

100% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 2

50% more funds holding

Funds holding: 6 [Q1] → 9 (+3) [Q2]

0.04% less ownership

Funds ownership: 0.94% [Q1] → 0.9% (-0.04%) [Q2]

9% less capital invested

Capital invested by funds: $802K [Q1] → $727K (-$74.8K) [Q2]

See Fund Rankings

Financial journalist opinion

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

Management to host earnings call at 5:00PM Eastern Time, today. LOS ANGELES, CALIFORNIA / ACCESS Newswire / August 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar at 5:00 PM Eastern Time to provides an update on operations through the fiscal quarter that ended June 30, 2025.

eXoZymes Provides Second Quarter 2025 Update at 5PM EST Today

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

LOS ANGELES, CA / ACCESS Newswire / August 7, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.

eXoZymes to Host Second Quarter 2025 Update on Tuesday August 12, 2025, at 5PM EST

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

Using eXoZymes' AI-driven exozymes platform, NCTx has demonstrated lab scale validation with 4 grams of NCT produced at a 96% yield and with a purity higher than 99%. NCT project went from concept to gram scale production in 5 months and at a fraction of normal SynBio R&D cost.

eXoZymes Details Biomanufacturing Breakthrough: 4 Grams of NCT with Over 99% Purity

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

N-trans-caffeoyltyramine (NCT) is a natural bioactive compound attracting considerable interest from researchers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. Using eXoZymes' AI-driven platform, a new and proprietary approach to biomanufacturing of NCT - with all the scale-up advantages of an exozyme biosolution - has been developed: Progressing from concept to lab scale validation with gram-scale production in only 5 months and at a fraction of normal SynBio R&D cost.

eXoZymes Biomanufacturing Breakthrough: From Concept to Gram-Scale NCT in Only 5 Months

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

MONROVIA, CA / ACCESS Newswire / June 26, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - announced its role in the Meta-PURE initiative, a $9.2 million USD National Science Foundation (NSF) funded project under the CFIRE program aimed at transforming the scalability and accessibility of cell-free systems to expand real-world applications. Led by Georgia Tech with a coalition of top academic and industry groups, Meta-PURE will build a suite of standardized, interoperable ‘modules' for cell-free biomanufacturing, enabling plug-and-play modules that can rapidly shift between use cases - from high-value nutraceuticals, to essential chemicals or pharmaceuticals.

eXoZymes Selected as Core Industry Partner in $9M NSF-Funded Initiative to Advance Modular Cell-Free Biomanufacturing

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

MONROVIA, CALIFORNIA / ACCESS Newswire / May 16, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - was featured on the latest episode of the Grow Everything podcast, revealing how the company's AI-engineered exozymes are reshaping the next generation of biomanufacturing by enabling sustainable chemical production outside of living cells. Considered one of the leading podcasts in biotechnology, the Grow Everything podcast is co-hosted by biotech experts, Erum Azeez Khan and Karl Schmieder, M.S.

eXoZymes Highlights Scalable Biomanufacturing Platform and First Spinout, NCTx, on Grow Everything Podcast

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

Management to host earnings call at 5:00PM Eastern Time, today. MONROVIA, CA / ACCESS Newswire / May 12, 2025 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into essential nutraceuticals, medicines, biofuels, and other valuable chemicals - provides an update on operations through the fiscal quarter that ended March 31, 2025, as well as the launch of the purpose-built subsidiary, NCTx.

eXoZymes Provides First Quarter 2025 and NCTx Subsidiary Update at 5PM EST Today

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

MONROVIA, CA / ACCESS Newswire / May 7, 2025 / eXoZymes Inc. (NASDAQ:EXOZ) ["eXoZymes"] - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Monday, May 12, 2025 at 5:00 PM Eastern Time to discuss its results for the first quarter of 2025, as well as share more details around the newly formed purpose-built subsidiary, NCTx. Michael Heltzen, CEO of eXoZymes, will lead the call and will be joined by select members of the management team to review recent developments, ongoing initiatives, anticipated milestones, as well as host a question-and-answer session.

eXoZymes to Host First Quarter 2025 and Subsidiary NCTx Update on Monday May 12, 2025, at 5PM EST

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

N-trans-caffeoyltyramine (NCT) is a natural product compound attracting considerable interest from researchers and drug developers for its potential role in healthy liver fat metabolism, gut barrier function, and mitochondrial activity. eXoZymes used its AI-driven development platform to progress from idea to purpose-built subsidiary in less than 3 months and at a fraction of normal SynBio R&D cost.

eXoZymes Launches Subsidiary, NCTx, to Unlock a Promising Compound for Gut and Liver Health

Bringing clarity and precision to the cell-free space by introducing exozymes

Scientific definition of exozymes featured as cover story in GEN Biotechnology, freely available as an Open Access paper The author team introduces the terms ‘exozymes' to bring clarity to the rapidly evolving field of cell-free biomanufacturing—a biomanufacturing method to produce chemicals without relying on living cells like bacteria or yeast The paper features co-authors from multiple institutions such as The National Renewable Laboratory (NREL), UCLA, Caltech, University of Colorado Boulder, Sepia Biosciences, as well as the venture studio, Ferment The authors intend the terms to be freely available for use by the broader scientiﬁc community, and no trademarks have been ﬁled Monrovia, CA, April 21, 2025 (GLOBE NEWSWIRE) -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - is featured as the cover story in the April issue of the peer-reviewed journal, GEN Biotechnology. Dr. Tyler Korman, co-founder and VP of Research at eXoZymes, is excited about the 'exozymes' cover story in GEN Biotechnology, which is freely available as an Open Access paper The Perspective paper called “Exozymes for Biomanufacturing: Toward Clarity and Precision in the Cell-Free Space” focuses on providing a scientific definition of 'exozymes' to alleviate confusion surrounding use of the phrase 'cell-free' with an emphasis on its use in biomanufacturing.

Bringing clarity and precision to the cell-free space by introducing exozymes

See News Rankings

Charts implemented using Lightweight Charts™